Quantcast

First of many Neuro-Biotech’s licensed products, ‘SymPath(R) blood test’

October 4, 2010

BASEL, Switzerland/>, Oct. 4/> /PRNewswire-FirstCall/ – Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) Pursuant to the company’s press release issued the 30th of September 2010/>, the following is a brief review and explanation of the earlier statements concerning the first of many Neuro-Biotech’s licensed products, “SymPath(R) blood test”.

For a better understanding, an “in vitro” blood test is described as, a non evasive test, whereas the testing, as in the case of SymPath(R), is performed on a small amount of the patient’s blood. To date the SymPath(R) blood test has been tested on several thousand of patients whose results illustrate a success rate accuracy of 98.8%. The testing audits have been rigorously documented and have met every industry standard.

SymPath(R) is an indispensable tool with unprecedented results. Medical practitioners have long been waiting for a similar test to accurately and quantifiably diagnose those symptoms amongst patients as, depression and stress related disorders. What does this mean for physicians?

Firstly, SymPath(R) assists the medical practitioner in diagnosing patients, based on quantitative measurement, as precise as current cholesterol tests. SymPath(R) allows the medical practitioner to determine with accuracy the severity level of the patient’s anxiety or depressive state. The medical practitioner will now be able to state, based on an objective quantified measure, using this test, rather than subjectively determining the diagnosis, as is currently performed.

Furthermore SymPath(R) will eliminate the costly and highly inefficient trial and errors currently performed by physicians in prescribing their recommended remedy, which can waste time and further cause harm for both patients and physicians. For instance, patients suffering from depression or stress related disorders will now properly diagnosed immediately following the testing through Neuro-Biotech’s SymPath(R) test.

No more guessing, medical practitioners will now be able to not only obtain accurate results, moreover, they will be able to properly diagnose their patients and prescribe the appropriate therapeutic approach and continued follow up with the patients.

SymPath(R) testing and its look into the intricate workings of the diverse mechanisms of the brain shall considerably reduce a patient’s burden during these already difficult times, furnishing physicians with a medically proven test, allowing for precise, effective and speedy diagnosis.

Equally, the SymPath(R) test will also allow major employers and a multitude of organizations within the health industry such as insurance companies, health providers, health establishments and governments in their efforts in reducing inefficiencies and most importantly cost.

To obtain the background scientific documentation concerning SymPath(R), the company shall provide on its website within days and weeks to come, several reports, findings and other such documents.

For more information, do not hesitate to contact us by writing to info@neuro-agora.com and your request will be transferred to the appropriate persons and we will get back to you as soon as possible.

    Contact:
    Neuro-Biotech Corp.
    Dr Claude Poulin
    41 61 500 05 16
    info@neuro-agora.com
    www.neuro-biotechcorp.com

Forward Looking Statements

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as “anticipates,” “believes,” “could,” “expects,” “intends,” “may,” “projects,” “targets” and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company’s actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company’s actual results to differ materially from those indicated in any forward-looking statements.

SOURCE Neuro-Biotech Corp.


Source: newswire



comments powered by Disqus